Global PEGylated Proteins Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type (Colony Stimulating Factors, Interferons, Erythropoietin, Recombinant Factor VIII, Monoclonal Antibodies, Others), By Application (Oncology, Gastrointestinal Disorders, Hepatitis, Chronic Kidney Diseases, Multiple Sclerosis, Others), By End Users (Pharmaceutical And Biopharmaceutical Companies, Research Institutes, CROs), And By Geography - Forecasts From 2021 To 2026

  • Published : Jun 2021
  • Report Code : KSI061612087
  • Pages : 120

The global PEGylated proteins market is expected to reach US$1,190.215 million by 2026 from US$680.263 million in 2019 growing at a CAGR of 8.32%. 

Protein PEGylation is the covalent attachment of polyethylene glycol (PEG) groups to protein to enhance the activity of the protein in vivo. The general idea behind protein PEGylation is to improve the physical and chemical properties of the protein and to enhance the bioactivity of conjugated protein. PEGylation of therapeutic proteins is becoming necessary owing to PEG's ability to protect against protein enzymatic degradation and increase the half-life of drugs. PEGylated proteins offer advantages such as extended half-life, reduced toxicity, lower immunogenicity, and increase in proteolytic protection which is accelerating the market growth of PEGylated proteins.

The key drivers of the market are the increasing adoption of PEGylated protein-based drugs due to increased stability and circulating half-life, increasing investments in research and development by pharmaceutical and biopharmaceutical companies, expansion in the biologics sector, increasing prevalence of lifestyle disease, rising focus, and awareness on strategies to improve protein stability and circulating half-life, are expected to boost the market growth during the forecast period. For instance, Mabwell Bioscience Co., Ltd., in September 2020, began the phase III clinical study to investigate the immunogenicity, safety, and hemostatic efficacy of PEGylated recombinant FVIII (BAX 855) in the patients who were previously left untreated and met the requirements of being less than 6 years old and have severe hemophilia A. In addition, the increasing adoption of PEGylated protein to treat various chronic diseases will further fuel the market, as the number of people infected with chronic disease is on a rise. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020.

By type, the colony-stimulating factors segment is expected to hold a significant market share due to the increasing rate of cancer patients and infections related to chemotherapy, across the globe. The interferon segment is also expected to have a prominent market share due to its increasing use in viral infections. By application, the oncology segment is projected to hold a dominant market share owing to the increasing prevalence of cancer-infected patients across the globe. According to World Health Organization, cancer is the second leading cause of death, amounting to an estimated 9.6 million deaths, or one in six deaths, in 2018, globally. By end-user application, pharmaceutical and biopharmaceutical companies are expected to hold a notable market share owing to the developments and investments in the sector to cater to the increasing demand. Geographically, North America is estimated to hold the majority market share due to the increasing adoption of biologics drugs such as monoclonal antibodies, erythropoietin, and interferon for the treatment of chronic diseases, increasing prevalence of cancer, investments in research activities for drug discovery at early stages, etc. The United States is considered to have a large number of cancer patients which will further propel the growth of the market. According to Global cancer statistics, in 2020, in the United States, approximately 2,281,658 cancer cases were diagnosed 2020, and 612,390 deaths were reported due to cancer. Furthermore, the Asia Pacific market is expected to grow during the forecast period owing to the increasing applications of PEGylated proteins in treating cancer, blood disorders, and chronic diseases.

pegylated proteins market

The Global PEGylated Proteins Market is segmented on the basis of Type, Application, End-User Industry, and Geography.

  • On the basis of Type, the Global PEGylated Proteins Market can be segmented into Colony Stimulating Factors, Interferons, Erythropoietin, Recombinant Factor VIII, Monoclonal Antibodies, and Others.
  • On the basis of Application, the Global PEGylated Proteins Market can be segmented into Oncology, Gastrointestinal Disorders, Hepatitis, Chronic Kidney Diseases, Multiple Sclerosis, and Others.
  • On the basis of the End-User Industry, the Global PEGylated Proteins Market can be segmented into Pharmaceutical and Biopharmaceutical Companies, Research Institutes, and CROs.
  • On the basis of Geography, the Global PEGylated Proteins Market can be segmented into North America, South America, Europe, Middle East, and Africa, and the Asia Pacific.

Growth Factor

  • Increasing use of colony-stimulating factors

Colony-stimulating factors are substances, which help support a person's immune system during cancer treatment. The increasing incidence of cancer across the globe has increased the demand for this segment, which in turn will fuel the market growth for PEGylated proteins, globally. According to Global cancer statistics, 2020, the number of cancer cases globally was estimated to be 19, 292,789, with nearly 9,958,133 deaths due to cancer. Thus, the need for colony-stimulating factors for the effective treatment of cancer will drive market growth.

Restraint

  • Failures in drug development

The development of drugs is a complex and challenging process. The chances of a drug being developed during the first trial are rare as failures in drug development are very prevalent. The overall failure rate in drug development is around 96%, including a 90% failure rate during clinical development. The consequence of an expensive drug failure for pharmaceutical companies ranges from site closures, loss of jobs, and exhausting research and development budgets. Thus, failures in drug development and rising recalls of the therapeutic drugs might hamper the growth of the PEGylated proteins market during the forecast period.

Covid 19 Impact On PEGylated Proteins Market

The novel coronavirus pandemic did not adversely affect the PEGylated Proteins Market. The demand for PEGylated proteins remained unaffected as they fall under necessities. Several research institutes conducted extensive research based on PEGylation technology, in 2020. For instance, in a research study published in the Journal of General Virology, 2020, SARS-CoV-2 replication could be inhibited by low concentrations of PEG-IFN-alpha-2a that inhibit MERS-CoV replication in cell culture. The impact of Covid-19, on the PEGylated Proteins market, was minimal.

Competitive Insights

Prominent/major key market players in the global PEGylated Proteins Market include Celares GmbH, Profacgen, JenKem Technology USA, Merck KGaA, QuiaPEG Pharmaceuticals Holding AB, Belrose Pharma Inc., Thermo Fisher Scientific Inc., Creative PEGWorks, NOF Corporation, and Biomatrik Inc. The players in the global PEGylated Proteins Market are implementing various growth strategies to gain a competitive advantage over their competitors in this market. Major market players in the market have been covered along with their relative competitive strategies in this report and the report mentions recent deals and investments of different market players over the last few years. The company profiles section details the business overview, financial performance (public companies) for the past few years, key products and services being offered along with the recent deals and investments of these important players in the global PEGylated Proteins Market.

PEGylated Proteins Market Scope:

Report Metric Details
 Market size value in 2019  US$680.263 million
 Market size value in 2026  US$1,190.215 million
 Growth Rate  CAGR of 8.32% from 2019 to 2026
 Base year  2019
 Forecast period  2021–2026
 Forecast Unit (Value)  USD Million
 Segments covered  Type, Application, End-User, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered  Celares GmbH, Profacgen, JenKem Technology USA, Merck KGaA, QuiaPEG   Pharmaceuticals Holding AB, Belrose Pharma Inc., Thermo Fisher Scientific Inc.,   Creative PEGWorks, NOF Corporation, Biomatrik Inc.
 Customization scope  Free report customization with purchase

 

Segmentation:

  • By Type
    • Colony Stimulating Factors
    • Interferons
    • Erythropoietin
    • Recombinant Factor VIII
    • Monoclonal Antibodies
    • Others
  • By Application
    • Oncology
    •  Gastrointestinal Disorders
    • Hepatitis
    • Chronic Kidney Diseases
    • Multiple Sclerosis
    • Others
  • By End-User
    • Pharmaceutical and Biopharmaceutical Companies
    • Research Institutes
    • CROs
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • UK
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • Israel
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Others

Frequently Asked Questions (FAQs)

Q1. What will be the PEGylated proteins market size by 2026?
A1. The PEGylated proteins market is expected to reach a market size of US$1,190.215 million by 2026.


Q2. What is the size of the global PEGylated proteins market?
A2. PEGylated Proteins Market was valued at US$680.263 million in 2019.


Q3. What are the growth prospects for the PEGylated proteins market?
A3. The global PEGylated proteins market is expected to grow at a CAGR of 8.32% over the forecast period.


Q4. What factors are anticipated to drive the PEGylated proteins market growth?
A4. PEGylated proteins offer advantages such as extended half-life, reduced toxicity, lower immunogenicity, and increase in proteolytic protection which is accelerating the growth of the PEGylated proteins market.


Q5. Which region holds the largest market share in the PEGylated proteins market?
A5. Geographically, North America is estimated to hold a significant share in the PEGylated proteins market due to the increasing adoption of biological drugs.


1.Introduction

1.1.Market Definition

1.2.Market Segmentation

 

2.Research Methodology

2.1.Research Data

2.2.Assumptions

 

3.Executive Summary

3.1.Research Highlights

 

4.Market Dynamics

4.1.Market Drivers

4.2.Market Restraints

4.3.Porters Five Forces Analysis

4.3.1.Bargaining Power of Suppliers

4.3.2.Bargaining Power of Buyers

4.3.3.The threat of New Entrants

4.3.4.Threat of Substitutes

4.3.5.Competitive Rivalry in the Industry

4.4.Industry Value Chain Analysis

4.5.Industry Regulations

4.6.Scenario Analysis

 

5.Global PEGylated Proteins Market Analysis, By Type

5.1.Colony Stimulating Factors

5.2.Interferons

5.3.Erythropoietin

5.4.Recombinant Factor VIII

5.5.Monoclonal Antibodies

5.6.Others

 

6.Global PEGylated Proteins Market Analysis, By Application

6.1.Oncology

6.2.Gastrointestinal Disorders

6.3.Hepatitis

6.4.Chronic Kidney Diseases

6.5.Multiple Sclerosis

6.6.Others

 

7.Global PEGylated Proteins Market Analysis, By End-User Industry

7.1.Pharmaceutical and Biopharmaceutical Companies

7.2.Research Institutes

7.3.CROs

 

8.Global PEGylated Proteins Market Analysis, By Geography

8.1.Introduction

8.2. North America

8.2.1.North America PEGylated Proteins Market Analysis, By Type, 2020 to 2026

8.2.2.North America PEGylated Proteins Market Analysis, By Application, 2020 to 2026

8.2.3.North America PEGylated Proteins Market Analysis, By End-User, 2020 to 2026

8.2.4.By Country

8.2.4.1. United States

8.2.4.2. Canada

8.2.4.3. Mexico

8.3.South America

8.3.1.South America PEGylated Proteins Market Analysis, By Type, 2020 to 2026

8.3.2.South America PEGylated Proteins Market Analysis, By Application, 2020 to 2026

8.3.3.South America PEGylated Proteins Market Analysis, By End-User, 2020 to 2026

8.3.4.By Country

8.3.4.1. Brazil

8.3.4.2. Argentina

8.3.4.3. Others

8.4.Europe

8.4.1.Europe PEGylated Proteins Market Analysis, By Type, 2020 to 2026

8.4.2.Europe PEGylated Proteins Market Analysis, By Application, 2020 to 2026

8.4.3.Europe PEGylated Proteins Market Analysis, By End-User, 2020 to 2026

8.4.4.By Country

8.4.4.1. UK

8.4.4.2. Germany

8.4.4.3. France

8.4.4.4. Spain

8.4.4.5. Others

8.5.The Middle East and Africa

8.5.1.Middle East and Africa PEGylated Proteins Market Analysis, By Type, 2020 to 2026

8.5.2.Middle East and Africa PEGylated Proteins Market Analysis, By Application, 2020 to 2026

8.5.3.Middle East and Africa PEGylated Proteins Market Analysis, By End-User, 2020 to 2026

8.5.4.By Country

8.5.4.1. Saudi Arabia

8.5.4.2. Israel

8.5.4.3. Others

8.6.Asia Pacific

8.6.1. Asia Pacific PEGylated Proteins Market Analysis, By Type, 2020 to 2026

8.6.2.Asia Pacific PEGylated Proteins Market Analysis, By Application, 2020 to 2026

8.6.3.Asia Pacific PEGylated Proteins Market Analysis, By End-User, 2020 to 2026

8.6.4. By Country

8.6.4.1. Japan

8.6.4.2. China

8.6.4.3. India

8.6.4.4. South Korea

8.6.4.5.Others

 

9.Competitive Intelligence

9.1. Competitive Benchmarking and Analysis

9.2. Recent Investment and Deals

9.3. Strategies of Key Players

 

10. Company Profiles

10.1.Celares GmbH

10.2.Profacgen

10.3.JenKem Technology USA

10.4.Merck KGaA

10.5.QuiaPEG Pharmaceuticals Holding AB

10.6.Belrose Pharma Inc.

10.7.Thermo Fisher Scientific Inc.

10.8.Creative PEGWorks

10.9.NOF Corporation

10.10.Biomatrik Inc.


Celares GmbH

Profacgen

JenKem Technology USA

Merck KGaA

QuiaPEG Pharmaceuticals Holding AB

Belrose Pharma Inc.

Thermo Fisher Scientific Inc.

Creative PEGWorks

NOF Corporation

Biomatrik Inc.